21 CFR Part 820 QMSR Implementation Services (FDA Quality System Regulation)
Our 21 CFR Part 820 implementation services support medical device organisations in developing and implementing a compliant Quality Management System Regulation (QMSR) aligned with FDA requirements. Patient Guard provides expert guidance to ensure your Quality Management System (QMS) meets US FDA expectations and is inspection-ready.
21 CFR Part 820 QMSR Implementation Services
21 CFR Part 820, now known as the FDA Quality Management System Regulation (QMSR), establishes quality management system requirements for manufacturers of finished medical devices intended for the U.S. market.
Effective from 2 February 2026, the QMSR incorporates ISO 13485:2016 by reference, bringing FDA quality system requirements into closer alignment with the internationally recognised medical device quality management standard while maintaining additional FDA-specific regulatory requirements.
Manufacturers subject to 21 CFR Part 820 must establish and maintain a Quality Management System appropriate to their devices and activities, covering applicable processes throughout design, manufacture, packaging, labelling, storage, installation and servicing.
Patient Guard provides expert 21 CFR Part 820 QMSR implementation services, helping medical device manufacturers establish, transition, remediate and maintain Quality Management Systems aligned with both FDA QMSR and ISO 13485:2016 requirements.
Our consultants can support the complete implementation process, from initial gap analysis and QMS planning through procedure development, process implementation, staff training, internal auditing and FDA inspection readiness.
For organisations already operating an ISO 13485 Quality Management System, we can assess the existing QMS against the additional requirements and terminology of the FDA QMSR, helping identify and address gaps before FDA inspection.
Whether you are entering the U.S. medical device market for the first time, transitioning from the former FDA Quality System Regulation, or strengthening an existing QMS, Patient Guard provides a practical and structured approach to achieving and maintaining 21 CFR Part 820 QMSR compliance.
Why Choose Patient Guard for QMSR Implementation?
QMSR Gap Analysis
We assess your existing Quality Management System against 21 CFR Part 820 QMSR and ISO 13485:2016 requirements to identify gaps, risks, and priorities for implementation.
ISO 13485 Alignment
We help align your QMS with ISO 13485:2016 while addressing the additional FDA-specific requirements needed for U.S. regulatory compliance.
Practical QMS Implementation
We develop and implement clear, proportionate procedures and processes that reflect your organisation, device portfolio, and operational activities.
FDA Inspection Readiness
We prepare your organisation for FDA inspection by reviewing documentation, records, implementation evidence, responsibilities, and areas commonly scrutinised by investigators.
Documentation & Process Control
We support development and remediation of key QMS processes including document control, CAPA, supplier controls, production controls, complaints, and management review.
Ongoing Compliance Support
Our support can continue after implementation through internal audits, QMS maintenance, remediation, training, and preparation for future FDA inspections.
What Our 21 CFR Part 820 Implementation Service Includes
QMS Gap Analysis
Reviewing your existing Quality Management System against 21 CFR Part 820 QMSR, ISO 13485:2016 and applicable FDA-specific requirements to identify compliance gaps and implementation priorities.
QMS Documentation
Developing and updating quality manuals, policies, procedures, forms and records required to establish a structured and effective FDA-compliant Quality Management System.
Design & Development Controls
Implementing appropriate processes for design and development planning, design inputs and outputs, verification, validation, design changes and transfer where applicable.
Production & Supplier Controls
Establishing processes for purchasing and supplier management, production controls, process validation, identification, traceability and other applicable operational activities.
CAPA & Post-Market Processes
Developing processes for nonconformities, corrective and preventive action, complaints, servicing and other post-market information to support effective quality management and regulatory compliance.
Training & Inspection Readiness
Supporting QMS implementation through staff training, internal audits and readiness activities to help ensure your organisation is prepared for FDA inspection.
Who Requires 21 CFR Part 820 Implementation?
- Medical device manufacturers entering the US market
- Organisations undergoing FDA inspections
- Companies with FDA compliance gaps or remediation needs
- Start-ups developing medical devices for US distribution
- Contract manufacturers and specification developers
21 CFR Part 820 Requirements Overview
Under the U.S. FDA regulatory framework, medical device manufacturers subject to 21 CFR Part 820 must establish and maintain a Quality Management System that meets the requirements of the FDA Quality Management System Regulation (QMSR).
Effective from 2 February 2026, the QMSR incorporates ISO 13485:2016 by reference while retaining additional FDA-specific requirements that manufacturers must address within their Quality Management System.
A comprehensive 21 CFR Part 820 QMSR-compliant Quality Management System typically includes:
| No | Heading | Contents |
|---|---|---|
| 1. | QMS Governance & Management | Quality objectives, organisational responsibilities, management commitment, management review and oversight of the Quality Management System. |
| 2. | Document & Record Control | Processes for creating, approving, controlling, maintaining and retaining QMS documents and quality records. |
| 3. | Design & Development | Design planning, inputs, outputs, reviews, verification, validation, transfer and control of design and development changes, where applicable. |
| 4. | Supplier & Production Controls | Supplier evaluation and monitoring, purchasing controls, production processes, process validation, identification and traceability, as applicable. |
| 5. | Risk & CAPA Processes | Risk-based quality processes, nonconformity management, corrective action and continual improvement activities. |
| 6. | Complaints & FDA Reporting | Complaint handling processes and integration with applicable FDA requirements for Medical Device Reporting, corrections and removals. |
| 7. | Audits & Inspection Readiness | Internal audits, management review, QMS effectiveness monitoring, staff readiness and preparation for FDA inspections. |
Our Process
Initial consultation
We assess your organisation, products, and FDA regulatory requirements.
Gap analysis
We identify areas requiring development to meet QSR requirements.
QMS development
We build your QMS aligned with FDA expectations.
Training and implementation
We support rollout and train your team on FDA compliance.
Inspection readiness
We prepare your organisation for FDA inspections and audits.
Industries We Support
We support QSR implementation across:
- Medical device manufacturers
- IVD manufacturers
- Software as a Medical Device (SaMD)
- Contract manufacturers
- Healthcare technology companies
Cost of Service
CFR 21 Part 820 Quality System Regulation Implementation
From
Ensure quality compliance and readiness with expert CFR 21 Part 820 QSR implementation support. Pricing starts from £5,850 for a basic implementation.
Features
- Full CFR 21 Part 820 compliant QMS development tailored to your business
- Gap analysis and implementation roadmap
- Internal audit and management review support
- End-to-end support
Time Lines
Week 1–2 – Gap Analysis & Planning
Assess current processes and define the CFR 21 Part 820 implementation roadmap
Week 3–6 – QMS Development & Implementation
Develop documentation, map processes, and implement the Quality Management System
Week 7–20 – Audit Readiness
Conduct internal audits and prepare for inspection audits
Implementation typically takes between 4–20 weeks, depending on the size and complexity of your organisation
Frequently Asked Questions (FAQs)
What is 21 CFR Part 820?
CFR Part 820 is the FDA Quality System Regulation governing quality systems for medical device manufacturers selling in the United States.
Is 21 CFR Part 820 mandatory?
Yes, compliance is mandatory for organisations marketing medical devices in the US.
How long does QSR implementation take?
Implementation typically takes between 8–20 weeks depending on organisation size and complexity.
How does QSR compare to ISO 13485?
QSR and ISO 13485 are closely aligned, but QSR includes specific FDA requirements such as complaint handling and MDR reporting.
What happens during an FDA inspection?
FDA inspections assess compliance with QSR requirements and may result in observations (Form 483) if issues are identified.
Related Services
Click on the links below to discover more:
- CFR 21 Part 820 QSR Internal Audits
- ISO 13485 Implementation
- IEC/ISO 27001 Implementation
- ISO 9001 Implementation
Recent Blog Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
IVDR Performance Evaluation Explained: A Complete Guide for Manufacturers
Performance Evaluation is one of the most important requirements under the EU In Vitro Diagnostic Regulation (IVDR). Every manufacturer must demonstrate that their in vitro diagnostic medical device achieves its intended purpose through robust scientific validity, analytical performance and clinical performance evidence. This guide explains every stage of IVDR Performance Evaluation, including Performance Evaluation Plans (PEPs), Performance Evaluation Reports (PERs), Post-Market Performance Follow-up (PMPF) and how Performance Evaluation supports successful CE marking under Regulation (EU) 2017/746.
IVDR Classification Explained: A Complete Guide to Class A, B, C and D IVDs
Understanding how your in vitro diagnostic device is classified under the EU IVDR is one of the first and most important steps towards regulatory compliance. This guide explains the IVDR classification rules, the differences between Class A, B, C and D IVDs, how Annex VIII is applied, and how classification affects conformity assessment, technical documentation and Notified Body involvement.
When Do You Need New Biocompatibility Testing for a Medical Device?
A material change, supplier switch, manufacturing transfer or design modification does not automatically require new ISO 10993 biocompatibility testing. Learn how manufacturers use Biological Evaluation Plans (BEPs), chemical characterisation, toxicological risk assessments and Biological Evaluation Reports (BERs) to determine whether existing biological evidence remains valid or whether additional testing is required under ISO 10993-1, the EU MDR and FDA expectations.
